Update on the role of antipsychotics in the treatment of Tourette syndrome.

Abstract

Tourette syndrome (TS) is a neuropsychiatric disorder with typical onset in childhood and characterized by chronic occurrence of motor and vocal tics. The disorder can lead to serious impairments of both quality of life and psychosocial functioning, particularly for those individuals displaying complex tics. In such patients, drug treatment is recommended. The pathophysiology of TS is thought to involve a dysfunction of basal ganglia-related circuits and hyperactive dopaminergic innervations. Congruently, dopamine receptor antagonism of neuroleptics appears to be the most efficacious approach for pharmacological intervention. To assess the efficacy of the different neuroleptics available, a systematic, keyword-related search in PubMed (National Library of Medicine, Washington, DC) was undertaken. Much information on the use of antipsychotics in the treatment of TS is based on older data. Our objective was to give an update and therefore we focused on papers published in the last decade (between 2001 and 2011). Accordingly, the present review aims to summarize the current and evidence-based knowledge on the risk-benefit ratio of both first and second generation neuroleptics in TS.

• Authors: Daniel Huys, Katja Hardenacke, Pia Poppe, Christina Bartsch, Burak Baskin, Jens Kuhn
• Journal: Neuropsychiatric disease and treatment (Neuropsychiatr Dis Treat) Vol. 8 Pg. 95-104 ( 2012) ISSN: 1178-2021 [Electronic] New Zealand
• PMID: 22442630 (Publication Type: Journal Article)